Insider trade

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY,
IN OR INTO THE UNITED STATES OF AMERICA, THE UNITED KINGDOM, AUSTRALIA,
CANADA, HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE
DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT
CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.

Oslo, 30 January 2026: Reference is made to the stock exchange announcement
published by Circio Holding ASA (the "Company") earlier today, 30 January
2026, regarding the final results of the rights issue and the private
placement.

The following primary insiders and close associates to primary insiders have
been allocated new shares and warrants in the Rights Issue and Private
Placement, including new shares and warrants as commission for their
pre-subscriptions in the Rights Issue:

* Erik Digman Wiklund, the CEO of the Company, has been allocated 150,000 new
shares and the corresponding number of warrants in the Rights Issue and
private placement. In addition, Erik Digman Wiklund has been granted 44,000
new shares and the corresponding number of warrants as commission for his
pre-subscription in the Rights Issue.

* Digman AS, a company closely associated with Erik Digman Wiklund, the CEO of
the Company, has been allocated 250,000 new shares and the corresponding
number of warrants in the Rights Issue and private placement.

* Ola Melin, Chief Operating Officer of the Company, has been allocated
150,000 new shares and the corresponding number of warrants in the Rights
Issue and private placement. In addition, Ola Melin has been granted 16,500
new shares and the corresponding number of warrants as commission for his
pre-subscription in the Rights Issue.

* Thomas Birkballe Hansen, Chief Technology Officer of the Company, has been
allocated 200,000 new shares and the corresponding number of warrants in the
Rights Issue and private placement. In addition, Thomas Birkballe Hansen has
been granted 22,000 new shares and the corresponding number of warrants as
commission for his pre-subscription in the Rights Issue.

* BioPharma Drug Licensing Group SL ("BioPharma"), a company closely
associated with Lubor Gaal, the CFO of the Company, has been allocated
270,000 new shares and the corresponding number of warrants in the Rights
Issue and private placement. In addition, Biopharma has been granted 29,700
new shares and the corresponding number of warrants as commission for
pre-subscription in the Rights Issue.

* Victor Levitsky, Chief Scientific Officer of the Company, has been allocated
250,000 new shares and the corresponding number of warrants in the Rights
Issue and private placement. In addition, Victor Levitsky has been granted
27,500 new shares and the corresponding number of warrants as commission for
his pre-subscription in the Rights Issue.

* Sølen AS, a close associate of Thomas Falck, board member of the board of
directors of the Company, has been allocated 200,000 new shares, and the
corresponding number of warrants in the Rights Issue and private placement.
In addition, Sølen AS has been granted 22,000 new shares and the
corresponding number of warrants as commission for pre-subscription in the
Rights Issue.

* Diane Mary Mellett, board member of the board of directors of the Company,
has been allocated 60,000 new shares and the corresponding number of
warrants in the Rights Issue and private placement. In addition, Diane Mary
Mellet has been granted 6,600 new shares and the corresponding number of
warrants as commission for her pre-subscription in the Rights Issue.

* Robert Forbes Burns, deputy member of the board of directors of the Company,
has been allocated 11,542 new shares and the corresponding number of
warrants in the Rights Issue and private placement.

* Damian Marron, the Chairman of the board of directors of the Company, has
been allocated 120,000 new shares and the corresponding number of warrants
in the Rights Issue and private placement. In addition, Damian Marron has
been granted 13,200 new shares and the corresponding number of warrants as
commission for his pre-subscription in the Rights Issue.

Please see the attached notifications of trade for information regarding the
subscription rights exercised by primary insiders in the Rights Issue and
Private Placement.

This stock exchange announcement was published by Mats Hermansen, VP Finance,
on behalf of the Company, at the time and date stated above in this
announcement.

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com

Lubor Gaal, CFO
Phone: +34 683 34 3811
Email: lubor.gaal@circio.com

About Circio
Building circular RNA expression systems for enhanced gene and cell therapies

Circio Holding ASA is a biotechnology company developing novel circular RNA
expression technology for gene and cell therapy.

Circio has established a unique circular RNA (circRNA) vector expression
technology for next generation RNA, DNA and viral therapeutics. The
proprietary circVec platform is based on a modular genetic construct designed
for efficient biogenesis of multifunctional circRNA inside target cells. The
circVec platform has applications in multiple therapeutic settings, including
genetic medicine, cell therapy and chronic disease. It has demonstrated
75-fold increased RNA half-life and up to 40-fold enhanced protein expression
vs. conventional mRNA-based viral and non-viral vector systems, with the
potential to become a new gold-standard gene expression technology. The
circVec R&D activities are being conducted by the wholly owned subsidiary
Circio AB in Stockholm, Sweden.

In parallel, Circio is continuing to develop its legacy immuno-oncology
program, TG01, through cost-efficient external academic and industry
collaborations. TG01 targets RAS-mutated cancers and is being tested in two
clinical trials in Norway and the USA. TG01 is a therapeutic peptide vaccine
adjuvanted by STIMULON QS-21 licensed from Agenus Inc.

-- IMPORTANT INFORMATION --
This announcement is not and does not constitute an offer of securities for
sale or a solicitation of an offer to purchase securities of the Company in
the United States or any other jurisdiction. Copies of this document may not
be sent to jurisdictions, or distributed in or sent from jurisdictions, in
which this is barred or prohibited by law. The securities of the Company may
not be offered or sold in the United States absent registration or an
exemption from registration under the U.S. Securities Act of 1933, as amended
(the "U.S. Securities Act").

The securities of the Company have not been, and will not be, registered under
the U.S. Securities Act. Any sale in the United States of the securities
mentioned in this communication will be made solely to "qualified
institutional buyers" as defined in Rule 144A under the U.S. Securities Act.
No public offering of the securities will be made in the United States.

Any offering of the securities referred to in this announcement will be made
by means of a prospectus (the "Prospectus") which will be prepared and which
is subject to the approval by the Norwegian Financial Supervisory Authority.
This announcement is an advertisement and is not a prospectus for the purposes
of Regulation (EU) 2017/1129 of the European Parliament and of the Council of
14 June 2017 on prospectuses to be published when securities are offered to
the public or admitted to trading on a regulated market, and repealing
Directive 2003/71/EC (as amended) as implemented in any EEA Member State (the
"Prospectus Regulation"). Investors should not subscribe for any securities
referred to in this announcement except on the basis of information contained
in the Prospectus. Copies of the Prospectus will, following publication, be
available from the Company's registered office and, subject to certain
exceptions, on the websites of the Managers.

In any EEA Member State other than Norway, this communication is only
addressed to and is only directed at qualified investors in that Member State
within the meaning of the Prospectus Regulation, i.e., only to investors who
can receive the offer without an approved prospectus in such EEA Member State.

In the United Kingdom, this communication is only addressed to and is only
directed at Qualified Investors who (i) are investment professionals falling
within Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (as amended) (the "Order") or (ii) are persons falling
within Article 49(2)(a) to (d) of the Order (high net worth companies,
unincorporated associations, etc.) (all such persons together being referred
to as "Relevant Persons"). These materials are directed only at Relevant
Persons and must not be acted on or relied on by persons who are not Relevant
Persons. Any investment or investment activity to which this announcement
relates is available only to Relevant Persons and will be engaged in only with
Relevant Persons. Persons distributing this communication must satisfy
themselves that it is lawful to do so.

This document is not for publication or distribution in, directly or
indirectly, Australia, Canada, Japan, the United States or any other
jurisdiction in which such release, publication or distribution would be
unlawful, and it does not constitute an offer or invitation to subscribe for
or purchase any securities in such countries or in any other jurisdiction. In
particular, the document and the information contained herein should not be
distributed or otherwise transmitted into the United States or to publications
with a general circulation in the United States of America.

The Manager is acting for the Company in connection with the Rights Issue and
no one else and will not be responsible to anyone other than the Company for
providing the protections afforded to its clients or for providing advice in
relation to the Rights Issue or any transaction or arrangement referred to in
this announcement.

Matters discussed in this announcement may constitute forward-looking
statements. Forward-looking statements are statements that are not historical
facts and may be identified by words such as "anticipate", "believe",
"continue", "estimate", "expect", "intends", "may", "should", "will" and
similar expressions. The forward-looking statements in this release are based
upon various assumptions, many of which are based, in turn, upon further
assumptions. Although the Company believes that these assumptions were
reasonable when made, these assumptions are inherently subject to significant
known and unknown risks, uncertainties, contingencies and other important
factors which are difficult or impossible to predict and are beyond its
control. Such risks, uncertainties, contingencies and other important factors
could cause actual events to differ materially from the expectations expressed
or implied in this release by such forward-looking statements. The
information, opinions and forward-looking statements contained in this
announcement speak only as at its date and are subject to change without
notice. This announcement is made by and is the responsibility of, the
Company. Neither the Manager nor any of its affiliates makes any
representation as to the accuracy or completeness of this announcement and
none of them accepts any responsibility for the contents of this announcement
or any matters referred to herein.

This announcement is for information purposes only and is not to be relied
upon in substitution for the exercise of independent judgment. It is not
intended as investment advice and under no circumstances is it to be used or
considered as an offer to sell, or a solicitation of an offer to buy any
securities or a recommendation to buy or sell any securities of the Company.
No reliance may be placed for any purpose on the information contained in this
announcement or its accuracy, fairness or completeness. Neither the Manager
nor any of its affiliates accepts any liability arising from the use of this
announcement.